Markets:

Overview

News

Currencies

International

Treasuries

Revolution Medicines, Inc. - Common Stock (NQ:RVMD)

188.34 +7.42 (+4.10%)

Streaming Delayed Price Updated: 12:05 PM EDT, Jul 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Revolution Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Revolution Medicines (NASDAQ:RVMD) Flashes Strong Technical Breakout Setup ↗

Today 8:20 EDT

Via Chartmill

Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now ↗

July 29, 2026

But is that performance sustainable?

Via The Motley Fool

This Stock Has Skyrocketed 125% in 2026 -- and Billionaire Stanley Druckenmiller Is Loading Up on It ↗

July 17, 2026

Revolution Medicines could be a revolutionary biotech stock.

Via The Motley Fool

Better Growth Buy: Axsome vs Revolution Medicines ↗

July 09, 2026

These stocks both scored a win in the first half of the year.

Via The Motley Fool

Topics Artificial Intelligence

Revolution Medicines Inc (NASDAQ:RVMD) Q1 2026 Loss Widens Amid Clinical Promise ↗

May 06, 2026

Via Chartmill

These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More ↗

July 06, 2026

These stocks have jumped in the double- and triple-digits.

Via The Motley Fool

Topics Artificial Intelligence Economy Stocks

Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy? ↗

July 05, 2026

The company recently wowed investors with clinical trial results.

Via The Motley Fool

Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd. ↗

July 01, 2026

This pre-commercial biotech is worth more than some drugmakers that generate consistent sales.

Via The Motley Fool

Can Revolution Medicines Be a Game-Changer Stock? ↗

June 11, 2026

This company's potential pancreatic cancer blockbuster could be a watershed moment.

Via The Motley Fool

Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock. ↗

June 05, 2026

Can the drugmaker justify its valuation?

Via The Motley Fool

Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally ↗

May 18, 2026

This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway cancers, advancing a pipeline of novel oncology candidates.

Via The Motley Fool

Topics Regulatory Compliance

Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase ↗

May 17, 2026

Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.

Via The Motley Fool

Topics Regulatory Compliance

Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally ↗

May 17, 2026

This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.

Via The Motley Fool

Topics Regulatory Compliance

Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares ↗

May 17, 2026

Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.

Via The Motley Fool

This Nuclear Tech Stock Grew Revenue 27%, But a Fund Still Slashed Its Stake ↗

May 15, 2026

Mirion Technologies delivers radiation detection and monitoring solutions to healthcare and industrial clients worldwide.

Via The Motley Fool

Topics Energy Regulatory Compliance

This Retail Stock Is Down 10% in a Year Despite Record Revenue. A Fund Just Cut Its Stake ↗

May 15, 2026

This global retailer offers apparel and accessories across multiple brands and channels in North America, Europe, and Asia.

Via The Motley Fool

Topics Regulatory Compliance

This Trade School Stock Is Up 135%. Here’s Why a Fund Still Bought 459,000 Shares ↗

May 15, 2026

Lincoln Educational Services delivers hands-on technical and healthcare training across 22 campuses, serving workforce needs nationwide.

Via The Motley Fool

Topics Regulatory Compliance

Callaway Stock Has Soared 150%. Here’s Why One Fund Still Bought 1.1 Million Shares ↗

May 15, 2026

Callaway Golf Company combines branded equipment sales with experiential entertainment through its Topgolf venues and lifestyle offerings.

Via The Motley Fool

Revolution (RVMD) Q1 2026 Earnings Transcript ↗

May 06, 2026

Revolution (RVMD) Q1 2026 Earnings Transcript

Via The Motley Fool

Revolution Medicines Has a Market Cap of $29 Billion and Generates No Revenue. Here's Why Its Valuation May Not Be as Ridiculous as It Seems ↗

April 27, 2026

The company has multiple drugs in its pipeline that could generate billions in revenue.

Via The Motley Fool

Revolution Medicines (RVMD): The New Titan of the RAS Pathway (2026 Research Feature)

April 15, 2026

As of April 15, 2026, the biotechnology sector is witnessing a paradigm shift in precision oncology, spearheaded by Revolution Medicines, Inc. (Nasdaq: RVMD). Once considered a high-risk clinical-stage...

Via Finterra

Topics Initial Public Offering

The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)

April 14, 2026

As of today, April 14, 2026, the biotechnology landscape is being reshaped by a singular clinical milestone that many once deemed impossible. Just twenty-four hours ago, Revolution Medicines, Inc....

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

Which stocks are moving on Monday? ↗

April 13, 2026

Here are the top movers in Monday's session, showcasing the stocks with significant price changes.

Via Chartmill

What's going on in today's session ↗

April 13, 2026

Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

These stocks are gapping in today's session ↗

April 13, 2026

Let's have a look at what is happening on the US markets on Monday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

Which stocks are moving before the opening bell on Monday? ↗

April 13, 2026

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗

March 22, 2026

Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead program advancing in clinical trials for breast cancer.

Via The Motley Fool

This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗

March 21, 2026

This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.

Via The Motley Fool

Topics Regulatory Compliance

This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth ↗

March 21, 2026

This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.

Via The Motley Fool

Topics Regulatory Compliance

This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash ↗

March 21, 2026

Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.

Via The Motley Fool

Topics Regulatory Compliance

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.